BioMarin projects 10% revenue growth to $3.1B-$3.2B for 2025, driven by VOXZOGO expansion
Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...
BioMarin: EPS Surges Past Expectations
Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...
BioMarin price target raised to $80 from $78 at Scotiabank
Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo ...
BioMarin price target raised to $113 from $109 at UBS
UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...